转移性结肠癌的一种新的治疗模式PPT.pptVIP

A new treatment paradigm for mCRC; Anti-EGFR antibodies in mCRC;Comparison of cetuximab and bevacizumab;Phase III CRYSTAL study: Study design;Study endpoints;KRAS analysis: Objective and methodology;KRAS evaluable population;Patient demographics at baseline according to KRAS status;ITT and KRAS evaluable population: Comparability;First-line ERBITUX + FOLFIRI: Correlation of KRAS status with efficacy;Relating KRAS status to efficacyPrimary endpoint: PFS – KRAS wild-type;Relating KRAS status to efficacyPrimary endpoint: PFS – KRAS mutant;Relating KRAS status to efficacy: PFS;Relating KRAS status to efficacySecondary endpoint: Response;Relating KRAS status to outcome:Most common grade 3/4 adverse events;Conclusions: CRYSTAL study;OPUS: Study design ;Phase II OPUS trial: KRAS analysis;KRAS evaluable population;Patient demographics at baseline;KRAS wild-type: n=134 (58%) ;Relating KRAS status to efficacySecondary endpoint: PFS – KRAS wild-type;Relating KRAS status to efficacySecondary endpoint: PFS – KRAS mutant;Relating KRAS status to efficacy:Progression-free survival;Most common grade 3/4 AEs;Conclusions: OPUS study;1. Van Cutsem E, et al. J Clin Oncol 2008;26 (Abstract No. 2); 2. Bokemeyer C, et al. J Clin Oncol 2008;26 (Abstract No. 4000);;Evidence of correlation between KRAS wild-type and EGFR inhibitor efficacy in chemorefractory CRC: Response;Role of KRAS mutations in predicting response, progression-free survival and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: Analysis of 281 individual data from published seriesAbstract O-018 – World Congress GI Cancer – Barcelona 2008Di Fiore F (1), Van Cutsem E (1), Laurent-Puig P (2), Siena S (3), Frattini M (4), De Roock W (1), Lievre A (2), Sartore-Bianchi A (3), Bardelli A (5), Tejpar S (1)(1) Digestive Oncology Unit, University Hospital Gasthuisberg, Leuven- Belgium; (2) Institut National d